Portfolio at a glance
Securities as at March 31, 2022
|
Company |
|
Number of securities |
|
Change since 31.12.2021 |
|
Local currency |
|
Share price |
|
Market value in CHF mn |
|
In % of securities |
|
In % of shareholders' equity |
|
In % of company |
|
Ionis Pharmaceuticals |
|
9 732 973 |
|
(500 000) |
|
USD |
|
37.04 |
|
332.6 |
|
10.7% |
|
12.0% |
|
6.9% |
|
Argenx SE |
|
920 538 |
|
(50 000) |
|
USD |
|
315.31 |
|
267.8 |
|
8.6% |
|
9.7% |
|
1.7% |
|
Moderna |
|
1 583 349 |
|
(80 000) |
|
USD |
|
172.26 |
|
251.6 |
|
8.1% |
|
9.1% |
|
0.4% |
|
Neurocrine Biosciences |
|
2 865 400 |
|
(150 000) |
|
USD |
|
93.75 |
|
247.8 |
|
7.9% |
|
9.0% |
|
3.0% |
|
Vertex Pharmaceuticals |
|
980 000 |
|
(50 000) |
|
USD |
|
260.97 |
|
235.9 |
|
7.6% |
|
8.5% |
|
0.4% |
|
Incyte |
|
2 756 000 |
|
(141 000) |
|
USD |
|
79.42 |
|
201.9 |
|
6.5% |
|
7.3% |
|
1.2% |
|
Intra-Cellular Therapies |
|
3 358 419 |
|
(180 000) |
|
USD |
|
61.19 |
|
189.6 |
|
6.1% |
|
6.9% |
|
3.6% |
|
Alnylam Pharmaceuticals |
|
1 050 000 |
|
(60 000) |
|
USD |
|
163.29 |
|
158.2 |
|
5.1% |
|
5.7% |
|
0.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Arvinas |
|
2 106 903 |
|
(70 000) |
|
USD |
|
67.30 |
|
130.8 |
|
4.2% |
|
4.7% |
|
4.0% |
|
Fate Therapeutics |
|
3 511 336 |
|
(190 000) |
|
USD |
|
38.77 |
|
125.6 |
|
4.0% |
|
4.5% |
|
3.6% |
|
Agios Pharmaceuticals |
|
4 092 292 |
|
(220 000) |
|
USD |
|
29.11 |
|
109.9 |
|
3.5% |
|
4.0% |
|
7.5% |
|
Relay Therapeutics |
|
3 885 962 |
|
(200 000) |
|
USD |
|
29.93 |
|
107.3 |
|
3.4% |
|
3.9% |
|
3.6% |
|
Sage Therapeutics |
|
3 010 104 |
|
(160 000) |
|
USD |
|
33.10 |
|
91.9 |
|
2.9% |
|
3.3% |
|
5.1% |
|
Revolution Medicines |
|
3 251 462 |
|
(170 000) |
|
USD |
|
25.51 |
|
76.5 |
|
2.5% |
|
2.8% |
|
4.4% |
|
Kezar Life Sciences |
|
4 668 148 |
|
(250 000) |
|
USD |
|
16.62 |
|
71.6 |
|
2.3% |
|
2.6% |
|
8.2% |
|
Myovant Sciences |
|
5 812 039 |
|
(310 000) |
|
USD |
|
13.32 |
|
71.4 |
|
2.3% |
|
2.6% |
|
6.2% |
|
Radius Health |
|
8 255 714 |
|
550 000 |
|
USD |
|
8.83 |
|
67.2 |
|
2.2% |
|
2.4% |
|
17.4% |
|
Macrogenics |
|
7 275 564 |
|
– |
|
USD |
|
8.81 |
|
59.1 |
|
1.9% |
|
2.1% |
|
11.9% |
|
Exelixis |
|
2 695 000 |
|
(140 000) |
|
USD |
|
22.67 |
|
56.4 |
|
1.8% |
|
2.0% |
|
0.8% |
|
Crispr Therapeutics |
|
902 105 |
|
(47 479) |
|
USD |
|
62.77 |
|
52.2 |
|
1.7% |
|
1.9% |
|
1.2% |
|
Molecular Templates |
|
10 992 003 |
|
200 000 |
|
USD |
|
3.45 |
|
35.0 |
|
1.1% |
|
1.3% |
|
19.5% |
|
Beam Therapeutics |
|
576 821 |
|
(30 000) |
|
USD |
|
57.30 |
|
30.5 |
|
1.0% |
|
1.1% |
|
0.8% |
|
Essa Pharma |
|
5 015 814 |
|
– |
|
USD |
|
6.18 |
|
28.6 |
|
0.9% |
|
1.0% |
|
11.4% |
|
Scholar Rock Holding |
|
2 165 125 |
|
(110 000) |
|
USD |
|
12.89 |
|
25.7 |
|
0.8% |
|
0.9% |
|
6.1% |
|
Generation Bio Co. |
|
3 663 180 |
|
(190 000) |
|
USD |
|
7.34 |
|
24.8 |
|
0.8% |
|
0.9% |
|
6.4% |
|
Esperion Therapeutics |
|
4 257 964 |
|
(220 000) |
|
USD |
|
4.64 |
|
18.2 |
|
0.6% |
|
0.7% |
|
6.8% |
|
Nektar Therapeutics |
|
2 960 676 |
|
340 000 |
|
USD |
|
5.39 |
|
14.7 |
|
0.5% |
|
0.5% |
|
1.6% |
|
Mersana Therapeutics |
|
3 925 000 |
|
(210 000) |
|
USD |
|
3.99 |
|
14.4 |
|
0.5% |
|
0.5% |
|
4.7% |
|
Wave Life Sciences |
|
4 562 858 |
|
(40 000) |
|
USD |
|
2.00 |
|
8.4 |
|
0.3% |
|
0.3% |
|
7.5% |
|
Black Diamond Therapeutics |
|
3 270 000 |
|
(170 000) |
|
USD |
|
2.77 |
|
8.4 |
|
0.3% |
|
0.3% |
|
9.0% |
|
Homology Medicines |
|
1 647 122 |
|
(90 000) |
|
USD |
|
3.04 |
|
4.6 |
|
0.1% |
|
0.2% |
|
2.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total securities |
|
|
|
|
|
|
|
|
|
3 118.7 |
|
100.0% |
|
113.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
|
1.8 |
|
|
|
0.1% |
|
|
|
Other payables |
|
|
|
|
|
|
|
|
|
(359.6) |
|
|
|
(13.0%) |
|
|
|
Net asset value |
|
|
|
|
|
|
|
|
|
2 760.9 |
|
|
|
100.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange rate as at 31.03.2022: USD/CHF: 0.9225